Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
Holding NBTX?
Track your performance easily
NBTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.57 - $8.96
Previous Close$4.07
Volume5.47K
Average Volume (3M)8.93K
Market Cap
$178.88M
Enterprise Value$137.48M
Total Cash (Recent Filing)$41.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.48
Next Earnings
Mar 13, 2025EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding47,133,328
10 Day Avg. Volume8,849
30 Day Avg. Volume8,926
Standard Deviation0.27
R-Squared0.00303
Alpha-0.00430
Financial Highlights & Ratios
Price to Book (P/B)-101.71
Price to Sales (P/S)4.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.79
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.50Price Target Upside200.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nanobiotix News
PremiumCompany Announcements
Nanobiotix’s Market Influence and Innovation Unveiled
PremiumCompany Announcements
Nanobiotix Strengthens Growth and Financial Prospects
PremiumCompany Announcements
Nanobiotix Showcases Innovation at Key Investor Events
PremiumCompany Announcements
Nanobiotix Updates Voting Rights and Capital Shares
PremiumCompany Announcements
Nanobiotix S.A. Showcases Half-Year ProgressPremiumCompany Announcements
Nanobiotix Reports Progress and Solid Financials
PremiumCompany Announcements
Nanobiotix Bolsters Board with Expert AdditionsPremiumCompany Announcements
Nanobiotix Engages in Premier Investment ConferenceBulls Say, Bears Say
Bulls Say
Market OpportunityThe ongoing global Phase III trial 'NANORAY-312' for NBTXR3 as a treatment for locally advanced head & neck cancer has a high probability of success, representing a significant commercial opportunity.
PartnershipNBTX entered into a global licensing and co-development & commercialization agreement with JNJ, which validates the potential for NBTXR3 and reduces development and commercialization risks.
ValuationNBTX ADRs are attractively valued relative to the commercial potential and development & commercialization risk of NBTXR3.
Bears Say
Development UncertaintyOutstanding questions on the development opportunity and path in this setting remain.
Financing NeedThe company has an acute financing need that has formed a major overhang on the stock.
Investor FocusInvestor focus largely remains on the company's cash runway and the ongoing Phase III NANORAY-312 study in locally advanced HNSCC.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
13.11% Other Institutional Investors
86.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $3.57 and its highest was $8.96 in the past 12 months.
What is Nanobiotix’s market cap?
Currently, no data Available
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Nanobiotix’s earnings last quarter?
Currently, no data Available
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -$0.69.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,133,327 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix?
Among the largest hedge funds holding Nanobiotix’s share is Perceptive Advisors LLC. It holds Nanobiotix’s shares valued at 3M.
---
Nanobiotix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
110.74%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix SA is a late-stage clinical company engaged in developing and selling nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company's products include NBTXR3, a preclinical research program for cancer immunotherapies.
---
NBTX Earnings Call
Q1 2024
0:00 / 0:00
---
NBTX Stock 12 Month Forecast
Average Price Target
$11.50
▲(200.26% Upside)
Technical Analysis
TG Therapeutics
―
Adaptimmune Therapeutics
―
Mereo Biopharma Group Plc
―
Fate Therapeutics
―
Best Analysts Covering NBTX
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-27.22%
reiterated a buy rating 10 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -27.22% per trade.
---